A company driven to create positive change and reduce the impact of disease on people’s lives
Nykode Therapeutics is an Oslo-based clinical-stage biopharmaceutical platform company founded in 2006. Our bold aim is to generate game-changing therapeutics to treat cancers and infectious diseases with a high unmet medical need.
With our unique and innovative modular vaccine technology, we’re specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting immune responses.
Nykode Therapeutics uplisted to the main list of the Oslo Stock Exchange
Leading the way with our pioneering vaccines
VB10.16
VB10.16 is our therapeutic vaccine for the treatment of human papillomavirus 16-induced malignancies. It has demonstrated positive interim efficacy and safety results from its Phase II trial for the treatment of cervical cancer.
VB10.NEO
The cancer neoantigen vaccine, VB10.NEO, is one of our lead product candidates and is exclusively out-licensed to Genentech. It is currently in Phase 1b trials for the treatment of locally advanced and metastatic tumors and Phase 1/2a trials for the treatment of melanoma, lung, head and neck, renal, and bladder cancers.
COVID-19 vaccine
Nykode has initiated a Phase 1/2 trial with two next-generation COVID-19 vaccine candidates.
Empowered by our long-standing partnerships
In our mission to bring our discoveries to the people who need them, we are proud to collaborate with world-class organizations. In oncology, our partners are Roche, Genentech, and Nektar Therapeutics. We have a multi-target collaboration with Regeneron within oncology and infectious diseases. For COVID-19 vaccine development, we have a strong relationship with Adaptive Biotechnologies.
